Marucci Laura, Lane Anne M, Li Wenjun, Egan Kathleen M, Gragoudas Evangelos S, Adams Judy A, Collier John M, Munzenrider John E
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1018-22. doi: 10.1016/j.ijrobp.2005.09.035. Epub 2006 Jan 10.
To evaluate the outcomes of a second course of proton beam radiation therapy (PBRT) in patients with recurrent uveal melanoma.
Thirty-one patients received a second course of PBRT. The mean interval between the first and the second PBRT course was 50.2 months (range, 8-165 months). Most patients (87%) received 70 cobalt Gray equivalent (CGE) for both courses. Visual acuity was 20/200 or better in 30 patients initially and in 22 patients at the second treatment. The mean follow-up time after the second treatment was 50 months (range, 6-164 months).
At the time of the last follow-up, 20 patients were classified as having no evidence of disease, defined as tumor regression or an absence of tumor progression. Nine eyes (29%) were enucleated because of local recurrence (n = 5) or intractable pain (n = 4). The 5-year eye retention rate was 55% (95% confidence interval: 25.2-77.4). Six of the 22 patients who retained the eye (27%) had useful vision (20/200 or better).
A second course of PBRT for recurrent uveal melanoma to total doses between 118 and 140 CGE was associated with a relatively good probability of local control and a low enucleation rate. Although most patients lost vision, the majority were able to retain the reirradiated eye. Further evaluation is needed to assess metastasis-free survival of additional proton irradiation vs. enucleation after local recurrence.
评估复发性葡萄膜黑色素瘤患者接受第二疗程质子束放射治疗(PBRT)的疗效。
31例患者接受了第二疗程的PBRT。第一疗程和第二疗程PBRT之间的平均间隔时间为50.2个月(范围8 - 165个月)。大多数患者(87%)两个疗程均接受70钴格雷当量(CGE)的照射。初始时30例患者视力为20/200或更好,第二次治疗时为22例。第二次治疗后的平均随访时间为50个月(范围6 - 164个月)。
在最后一次随访时,20例患者被分类为无疾病证据,定义为肿瘤消退或无肿瘤进展。9只眼(29%)因局部复发(n = 5)或顽固性疼痛(n = 4)而被摘除眼球。5年眼球保留率为55%(95%置信区间:25.2 - 77.4)。保留眼球的22例患者中有6例(27%)视力有用(20/200或更好)。
复发性葡萄膜黑色素瘤接受总剂量在118至140 CGE之间的第二疗程PBRT,局部控制概率相对较高且眼球摘除率较低。虽然大多数患者视力丧失,但大多数患者能够保留再次接受照射的眼球。需要进一步评估局部复发后额外质子照射与眼球摘除相比的无转移生存率。